Gene Therapy / Genes / Gene / Therapies / Therapeutics / Biopharma / BioPharma / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Achaogen / ADC Therapeutics / Akrevia Therapeutics / Alexandria Real Estate Equities / Artizan Biosciences / Bain Capital / BlackThorn Therapeutics / cancer / Catalyst Pharmaceuticals / Celsius Therapeutics / clinical trials / Columbia University / CRISPR / CymaBay Therapeutics / deals / diabetes / Eli Lilly / FDA / Genmab / Ginkgo BioWorks / GlaxoSmithKline / Grail / Hans Bishop / Immunotherapy / Ingeneron / Insys Therapeutics / Jacobus Pharmaceuticals / Jennifer Cook / Jennifer Doudna / Johnson & Johnson / Laboratory for Genomic Research / LaunchLabs / Life Sciences / Merck / nonalcoholic steatohepatitis / Novo Nordisk / Obsidian Therapeutics / pemphigus vulgaris / Provention Bio / Roche / Savara / Spark Therapeutics / startups / Synlogic / Tessa Therapeutics / Tetraphase Pharmaceuticals / Tilos Therapeutics / Trulicity / UCSF / VC / Yale University

Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More

Posted on: Jun 14, 2019   |   Posted by: Biotech Mag Top

Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More

Is one of the bigger biopharma acquisitions of the year in trouble? This past week, antitrust regulators once again delayed Roche's planned $4.8 billion buyout of gene therapy...

Continue reading ...



Other Posts from Biotech Mag Top